Liver Neoplasm Clinical Trial
The standard treatment of unresectable hepatocellular carcinoma (HCC) is transarterial
chemoembolization (TACE) or sorafenib. Though the TACE and the agent showed survival benefit
in several randomized phase III trials, the benefit was modest.
Recently, radiotherapy (RT), especially conformal and higher dose with the advancement of RT
techniques, showed favorable response rate with acceptable local control rate. Based on those
promising results, RT was actively applied in HCC who are not indicated with surgery and/or
radiofrequency ablation.
Many researchers reported that there is a relationship between RT dose and tumor response
rate. RT dose, however, is frequently limited because the complications (like radiation
induced liver disease (RILD), radiation induced gastro-duodenal toxicity, etc.) are also
closely related with higher exposed RT dose.
Proton beam has characteristic depth-dose distribution contrast to photon, the "Bragg peak".
The advantage of this dose distribution could be more highlighted in HCC management, because
of the weakness and maintenance importance of liver function itself in HCC patients. In fact,
the superior results of proton beam therapy in HCC were constantly reported in several groups
as prospectively as well as retrospectively.
In this background, the investigators planned the present study to evaluate the efficacy and
safety of proton beam therapy in HCC patients who are not indicated with surgery and/or
radiofrequency ablation (RFA).
Status | Recruiting |
Enrollment | 66 |
Est. completion date | November 2022 |
Est. primary completion date | October 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - Hepatocellular carcinoma (HCC) patients (Pathologically proven or HCC diagnosed based on American Association for the Study of Liver Diseases (AASLD) guideline) - Not indicated with surgical resection and/or RFA - Discussion in tumor board including gastroenterologist, radiologist, radiation oncologist - Eastern Cooperative Oncology Group performance status 0 to 2 within 1 week before participate - Adequate bone marrow function (absolute neutrophil count = 1.0 x 109/l, platelet = 30 x 109/l, hemoglobin = 8 g/dl) - Adequate liver/renal function within 1 week before participate - Total bilirubin <3.0 mg/dL, Prothrombin time/International normalized ratio <1.7, Albumin=2.8g/dL, Aspartate aminotransferase/alanine aminotransferase<6 times of upper normal limit Serum creatinine < 1.5 x upper normal limit, glomerular filtration rate > 50 ml/min - Informed consent - If viable tumor is single, 1 cm to 10 cm - Less than 3 nodules - Child-Pugh class A, B, or early C (score = 10) - Women of childbearing potential and male participants must agree to practice adequate contraception while on study and for at least 6 months following the last dose of RT Exclusion Criteria: - Uncontrolled hepatic encephalopathy - Previous history of upper abdominal radiotherapy - Status of pregnancy or breast feeding - Less than 12 weeks of expected survival - Uncontrolled ascites - Combined with disease known as radiosensitive disorder (connective tissue disorder, Ataxia-telangiectasia) - Hard to maintain stable respiration less than 5 minutes related with respiratory disease - Combined with uncontrolled severe acute disease other than liver |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Samsung Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | two-year overall survival | two-year after proton beam therapy | ||
Secondary | 1 month objective response rate | Modified Response Evaluation Criteria In Solid Tumors (mRECIST) will be used. | 1 month after proton beam therapy | |
Secondary | 3 month objective response rate | Modified Response Evaluation Criteria In Solid Tumors (mRECIST) will be used. | 3 months after proton beam therapy | |
Secondary | 6 month objective response rate | Modified Response Evaluation Criteria In Solid Tumors (mRECIST) will be used. | 6 months after proton beam therapy | |
Secondary | 1 year progression free survival | Modified Response Evaluation Criteria In Solid Tumors (mRECIST) will be used. | one-year after proton beam therapy | |
Secondary | 1 year local progression free survival | Modified Response Evaluation Criteria In Solid Tumors (mRECIST) will be used. | one-year after proton beam therapy | |
Secondary | 6 months adverse event | Common Terminology Criteria for Adverse Event v4.0 (CTCAE v4.0) will be used. | 6 months after proton beam therapy | |
Secondary | 1 year adverse event | Common Terminology Criteria for Adverse Event v4.0 (CTCAE v4.0) will be used. | 1 year after proton beam therapy | |
Secondary | Baseline Quality of life assessment by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30 (EORTC QLQ C-30) | Within 2 week before proton beam therapy started | ||
Secondary | 1 month Quality of life assessment by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30 (EORTC QLQ C-30) compared with baseline | 1 month after proton beam therapy | ||
Secondary | 3 month Quality of life assessment by EORTC QLQ C-30 compared with baseline | 3 month after proton beam therapy | ||
Secondary | 6 month Quality of life assessment by EORTC QLQ C-30 compared with baseline | 6 month after proton beam therapy | ||
Secondary | Baseline Indocyanine green (ICG) | ICG Retention rate at 15 minute will be used. | Within 2 week before proton beam therapy started | |
Secondary | Indocyanine green (ICG) test change compared with baseline | ICG Retention rate at 15 minute will be used. | 3 month after proton beam therapy | |
Secondary | Baseline hepatobiliary phase signal | Hepatobiliary phase (20 minute after gadoxetate disodium injection) will be used to evaluate functioning liver volume. | Within 2 week before proton beam therapy started | |
Secondary | Hepatobiliary phase signal change after proton beam therapy | Hepatobiliary phase (20 minute after gadoxetate disodium injection) will be used to evaluate functioning liver volume. | 3 month after proton beam therapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02557724 -
Mobilization of Mesenchymal Stem Cells During Liver Transplantation
|
||
Terminated |
NCT04702230 -
Value of Functional Magnetic Resonance Imaging of Hepatocellular Carcinoma After Transarterial Chemoembolization or Transarterial Radioembolization
|
||
Active, not recruiting |
NCT01217034 -
Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib
|
Phase 2 | |
Recruiting |
NCT05169177 -
Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy
|
||
Withdrawn |
NCT02599909 -
Gut Microbiota in People With Hepatocellular Carcinoma (HCC)
|
||
Terminated |
NCT03998033 -
Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
Recruiting |
NCT04010071 -
Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
|
Phase 2 | |
Recruiting |
NCT04864054 -
T-Cell Therapy (ECT204) in Adults With Advanced HCC
|
Phase 2 | |
Terminated |
NCT04187937 -
Feasibility of Ultrasound-based Navigation for Non-anatomical Liver Resections
|
N/A | |
Completed |
NCT02471313 -
Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
|
Phase 2 | |
Completed |
NCT00001576 -
A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver
|
Phase 1 | |
Recruiting |
NCT01542281 -
Pre-habilitation to Improve Outcomes in Patients Undergoing Liver Resection for Cancer
|
N/A | |
Recruiting |
NCT03803436 -
Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation
|
Phase 2 | |
Completed |
NCT05495529 -
Biliary or Digestive Protection by Room Air Interposition for Thermal Ablation of Central Hepatic Tumors
|
||
Completed |
NCT02571946 -
Proton Beam Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
|
N/A | |
Not yet recruiting |
NCT01180088 -
Effectiveness of Routine Application Of Anterior Approach During Right Hepatectomy
|
N/A | |
Withdrawn |
NCT00510627 -
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases
|
Phase 4 | |
Completed |
NCT05848947 -
SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA
|
Phase 4 | |
Not yet recruiting |
NCT05723705 -
Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT)
|
||
Terminated |
NCT04502082 -
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
|
Phase 1/Phase 2 |